Pembrolizumab vs chemotherapy as 2L therapy for advanced esophageal cancer: Japanese Subgroup Analysis in KEYNOTE-181
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz339.026
Abstract: Abstract Background Safe and effective treatment of advanced esophageal cancer is an area of unmet need. KEYNOTE-181 is a global, randomized, open-label, phase 3 study of pembrolizumab (PBR) vs chemotherapy (SoC) as second-line therapy for… read more here.
Keywords: esophageal cancer; keynote 181; therapy advanced; advanced esophageal ... See more keywords